CD34 and myelodysplastic syndrome: To date, aberrant expression of miR-34a and miR-155 has not been described in terminally differentiated granulocytes, although increases of miR-34a and miR-155 have previously been observed in CD34+ cells from patients with low- and high-risk MDS, respectively [41, 43].